Insider Trader Used Secret Trial Data for $65K Windfall!

SEC v. Rakesh Ahuja — U.S. Securities and Exchange Commission Litigation Release No. 26533, dated April 21, 2026.

The SEC charged Rakesh Ahuja, a former investment advisory firm employee, with insider trading. Ahuja allegedly used confidential clinical trial data and other nonpublic information obtained through his job to trade for a relative's brokerage account. The trades reportedly generated approximately $65,000 in profits.

In Plain English

Imagine you work at a company that helps people invest in new medicine companies. You get secret information about whether a new drug is working or not. Instead of keeping it secret, you tell a family member, who then uses that secret info to buy or sell stocks before everyone else knows. This is like knowing a surprise party is happening before the invitation is sent out and telling someone to bring a gift early.

Disclaimer: all facts are drawn from the SEC's own filings; the claims described are allegations unless and until a court rules or the parties settle, and some cases end in dismissal.

How the Alleged Scheme Worked

1. Access to Confidential Data Rakesh Ahuja worked as a senior associate at an investment advisory firm (IA Firm) that managed funds investing in biopharmaceutical and biotechnology companies. His job involved researching potential investments and conducting due diligence, giving him access to sensitive, nonpublic information about these companies.
2. Receiving Material Nonpublic Information As part of his due diligence process, Ahuja received material nonpublic information from the companies his firm was researching. This information included confidential clinical trial data, which was crucial for assessing the companies' future prospects.
3. Breach of Duty Ahuja owed a duty to his employer, IA Firm, to keep this confidential information private and not use it for personal benefit. He allegedly breached this duty by using the information without a business purpose.
4. Trading Through a Relative's Account On multiple occasions, Ahuja caused a brokerage account registered in the name of one of his close relatives to execute trades. These trades were based on the material nonpublic information he had obtained through his employment.
5. Timing of Trades The trades were strategically timed to occur in advance of significant announcements by the companies Ahuja was researching. This allowed the relative's account to profit from the price movements that occurred once the nonpublic information became public.
6. Multiple Instances Ahuja engaged in this conduct in connection with three publicly traded companies. The alleged insider trading occurred on a total of four separate occasions between June 2022 and July 2023.
7. Illicit Profits As a result of these unlawful trades, the brokerage account in the relative's name allegedly generated profits of approximately $65,000.
8. Attempted Deception In January 2024, after FINRA compiled a list of individuals potentially involved in suspicious trading, Ahuja resigned from IA Firm. He allegedly misrepresented his knowledge of the relative's name on the FINRA list on two separate occasions.

The Enforcement Action

On April 20, 2026, the SEC filed a settled action against Rakesh Ahuja, a former investment advisory firm employee, for insider trading. Ahuja allegedly used confidential information obtained during his employment, including clinical trial data, to trade in a relative's brokerage account ahead of company announcements. The trades resulted in approximately $65,000 in profits. Without admitting or denying the allegations, Ahuja agreed to a permanent injunction against violating antifraud provisions, a two-year bar from the investment advisory/brokerage industry, disgorgement of $65,404.25, prejudgment interest of $12,289.01, and a civil penalty of $65,404.25.

Named in this action: Rakesh Ahuja.

Original SEC litigation release ↗ · Browse all cases